Article info
Therapeutics
Systematic review
For type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non-insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic risk
- Correspondence to Srikanth Bellary
Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B95SS, UK; srikanth.bellary{at}heartofengland.nhs.uk
Citation
For type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non-insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic risk
Publication history
- First published March 21, 2011.
Online issue publication
March 21, 2011
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions